65438+1On October 29th, Guangdong Drug Trading Center issued the Notice on Carrying out Centralized Procurement and Registration of Chinese Patent Medicines such as Guangdong Alliance Qingkailing. After the procurement document of 202 1 65438+2 was issued at the end of February, the centralized procurement of Guangdong Chinese Patent Medicine Alliance made new progress.
Register three parties involved in quantity procurement, including production enterprises, distribution enterprises and medical institutions.
The registration process of production enterprises is relatively complicated. First, register the enterprise. After the enterprise registration takes effect, add products as required, or submit invalid products for review after information maintenance.
Production enterprises should pay attention to three points when signing up for this centralized procurement. First, the product specifications registered by the enterprise should include the product specifications with the largest pre-order quantity of the same variety in the first year reported by public medical institutions in the alliance area; Second, it is necessary to provide the corresponding capacity information of the enterprise; Finally, submit the letter of credit commitment as required.
The requirements of medical structure and distribution enterprises are relatively simple, and distribution enterprises and medical institutions that are not registered on provincial platforms can register at any time. After passing the qualification examination, the distribution enterprises and medical institutions complete the registration work.
The corresponding deadline for the publication of documents:
Deadline for product addition: from now until February 9, 2022 17:00.
Deadline for product submission: from now until11February 2022 17:00.
Deadline for registration of centralized procurement of alliance: from now until 15, February 2022 17:00.
The document emphasizes that the specific product specifications registered by the enterprise within the specified time are the list of supplied products, which cannot be revoked or modified after the registration deadline. If the enterprise's benchmark product specifications are really unable to participate in the registration due to production suspension, policies and other reasons, it shall provide specific information and submit the certification materials of the provincial drug regulatory authorities.
If the relevant enterprises fail to complete the above work within the time limit, they will be deemed to have voluntarily given up participating in the centralized procurement of the Union, and the corresponding consequences will be borne by the enterprises themselves.
Previously released procurement documents pointed out that exclusive products that were not selected/selected and non-exclusive products that were not selected/selected in the same group were independently purchased by Guangdong medical institutions according to the Guiding Opinions of Guangdong Medical Insurance Bureau on Purchasing Drugs and Medical Consumables. The provinces (autonomous regions) of the Union shall implement the provisions of the provinces (autonomous regions) on filing or monitoring products.
It can be seen that if we miss this collection because of mistakes, it will have a great impact on the market of related products under the enterprise.
Exclusive products meet the challenge.
It is common knowledge in the industry that it is difficult to collect Chinese patent medicines centrally. On the one hand, quality is difficult to evaluate; On the other hand, there are many exclusive varieties and insufficient competition. However, under the background of normalization of quantity procurement, quantity procurement of Chinese patent medicines is the only way.
In the past 20021year, Guangdong and Hubei took the lead in regional alliance procurement of Chinese patent medicines. Hubei Province took the lead 19 provincial alliance bid opening for centralized procurement of proprietary Chinese medicines, 157 enterprises 182 products participated in the quotation, and the procurement scale was nearly10 billion yuan; In the end, 97 enterprises,11products were selected, the winning rate reached 62%, and the average price dropped by 42.27%, with the largest drop of 82.63%.
The procurement documents for centralized collection of Chinese patent medicines in Guangdong have been released and the registration work has been started. It is expected that the next step will be taken after the year.
As a pathfinder, Hubei has made great achievements in centralized procurement of Chinese patent medicines, although there are disputes over the price differences of different selected products. According to the annual demand of 19 provincial alliance, it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan.
In addition, from the experience of centralized collection of Chinese patent medicines in Hubei, the exclusive varieties of Chinese patent medicines have also reduced their prices by a large margin, and they are also facing the pressure of price reduction.
For example, Ling Xing dropping pills of Beijing Shuanglu Pharmaceutical Co., Ltd. decreased from 40.93 yuan to 1 1.36 yuan, with a price reduction of 72.25%; Guangxi Wuzhou Pharmaceutical Xueshuantong for injection decreased from 336.8 yuan to 135.00 yuan, with a price reduction rate of 59.92%. Jiangxi Ji Min Credible Jinshuibao Tablets decreased from 6 1.08 yuan to 35.98 yuan, with a price reduction of 4 1.09%. The above manufacturers are either exclusive dosage forms or exclusive varieties, but the price reduction rate has exceeded 30%.
65438+1On October 27th, Guangdong Drug Trading Center held an online training meeting on centralized procurement of Chinese patent medicines such as Guangdong Alliance Qingkailing, to interpret the centralized procurement documents.
Guangdong has also adopted various price-fixing measures for exclusive varieties. On the one hand, it is divided into three groups according to the average daily cost, and on the other hand, the quantity and price are linked. The more the price is reduced, the more the distribution will be. It is expected that another batch of exclusive varieties will face price reduction by then. Many Chinese medicine companies in the market rely on exclusive varieties to survive, and the pressure is not small in this context.
03 Ma Jia Retail Market
At present, the development of quantity procurement of Chinese patent medicines is still in the exploratory stage, and both enterprises and officials need to further sort out and adapt to the rules. It will take time to verify the result, and it is still uncertain.
However, on the whole, the centralized collection of proprietary Chinese medicines will still be a favorable policy for the development of the Chinese medicine industry, and the market reshuffle will follow, and some Chinese medicine enterprises without core competitiveness will be eliminated by the times.
In this context, relevant enterprises can try to redistribute the market, increase R&D investment, build standardized planting bases of Chinese herbal medicines, improve quality standards, and set up professional academic self-promotion teams of Chinese herbal medicines to meet the challenges.
In the first year, Guangdong Patent Medicine Alliance purchased 3.995 billion tablets/capsules/bags/sticks, including 3.394 billion tablets/capsules/bags/sticks in public hospitals, 63 million tablets/capsules/bags/sticks in designated medical institutions and 65.438+0.38 billion tablets/capsules in retail pharmacies.
From the recent trend of centralized procurement, it can be seen that retail pharmacies have become another key area for quantity procurement, and some enterprises have begun to consider factors such as drug attributes and rationally allocate market resources.
In the centralized collection of Chinese patent medicines in 19 provinces led by Hubei, four varieties of China Resources Sanjiu participated in the quotation, three were injections, 1 was an oral product, and finally 1 was selected. However, China Resources Sanjiu believes that overall, the impact of centralized procurement on its business is relatively limited.
On the one hand, because the proportion of related varieties in the company's income is relatively small, on the other hand, the selected varieties will also bring certain protection. In addition, China Resources Sanjiu pointed out that its dental products are mainly aimed at the retail market, and the hospital market has done less, so the impact of not being selected is limited.
China Resources Sanjiu said that in the future, many drugs for chronic diseases will be adjusted on the basis of previous business and realized in the out-of-hospital market.
Attached: